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Abstract  
Objective 
To systematically evaluate the association between serum uric acid (SUA) level and 
subsequent development of type 2 diabetes (T2DM) 
 
Research Design and Methods 
We searched MEDLINE (1966 to 2009 Mar 31) and EMBASE (1980 to 2009 Mar 31) 
for observational cohort studies examining the association between SUA and the risk of T2DM 
by manual literature search. Relative risks (RRs) for each 1 mg/dl increase in SUA were pooled 
by using a random-effects model. The studies included were stratified into subgroups 
representing different study characteristics, and meta-regression analyses were performed to 
investigate the effect of these characteristics on the association between SUA and T2DM risk. 
 
Results 
The search yielded 11 cohort studies (42,834 participants) that reported 3305 incident 
cases of T2DM during follow-up periods ranging from 2.0 to 13.5 years. The pooled RR of a 1 
mg/dl increase in SUA was 1.17 (95% confidence interval (CI) 1.09–1.25). Study results were 
consistently significant (i.e. greater than 1) across characteristics of participants and study 
design. Publication bias was both visually and statistically suggested (P=0.03 for Egger’s test, 
0.06). Adjustment for publication bias attenuated the pooled RR per mg/dl increase in SUA (RR, 
1.11; 95% CI, 1.03-1.20), but the association remained statistically significant (P=0.009).  
 
Conclusions 
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The current meta-analysis suggests that SUA level is positively associated with the 
development of T2DM regardless of various study characteristics. Further research should 
attempt to determine whether it is effective to utilize SUA level as a predictor of T2DM for its 
primary prevention.  
4 
 
Introduction  
Identifying risk factors for the development of type 2 diabetes (T2DM) is essential for its 
early screening and prevention. Serum uric acid (SUA) level has been suggested to be associated 
with risk of T2DM. Biologically, uric acid (UA) plays an important role in worsening of insulin 
resistance (IR) in animal models by inhibiting the bioavailability of nitric oxide, which is 
essential for insulin-stimulated glucose uptake (1). However, hyperinsulinemia as a consequence 
of IR causes an increase in SUA concentration by both reducing renal UA secretion (2) and 
accumulating substrates for UA production (3). Therefore, it remains controversial whether SUA 
is independently associated with the development of T2DM. The aim of our meta-analysis was to 
summarize the association between SUA level and risk of T2DM derived from previously 
published cohort studies and to examine the effect of study characteristics on this association.  
 
 
Research Design and Methods  
Search Strategy 
The meta-analysis was fundamentally conducted according to the checklist of the 
Meta-analysis of Observational Studies in Epidemiology (4). We performed a systematic 
literature search of MEDLINE (1966 to 2009 Mar 31) and EMBASE (1980 to 2009 Mar 31) for 
observational cohort studies examining the association between SUA level and risk of T2DM. 
The keywords were related to SUA (combined exploded version of the Medical Subject Headings 
[MeSH] [uric acid] and the following text words [hyperuricemia OR (Acid AND Uric) OR 
Trioxopurine OR Trihydroxypurine OR Urate OR gout OR gouts]) and T2DM (combined 
unexploded version of MeSH [diabetes mellitus or diabetes mellitus, type 2] and the following 
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text words [Hyperglycemias OR Hyperglycemia OR (Diabetes Mellitus AND (Type 2 OR Type II 
OR Ketosis Resistant OR Ketosis-Resistant OR Maturity Onset OR Maturity-Onset OR 
Noninsulin Dependent OR Non Insulin Dependent OR Non-Insulin-Dependent OR Slow Onset 
OR Slow-Onset OR Stable OR Adult Onset OR Adult-Onset)) OR MODY OR NIDDM]). 
Included papers had to meet the following criteria: (1) prospective or historical cohort study; 
(2) inclusion of T2DM as a specified outcome; (3) baseline assessment of SUA level; and (4) 
inclusion of data on relative risk (RR), which is generally expressed as the odds ratio in a 
historical cohort study or the risk ratio in a prospective cohort study, and its corresponding 95% 
confidence intervals (CIs) (or data to calculate them) for T2DM associated with SUA level. When 
two or more studies were conducted using the same subjects, the study that included the most 
recently updated data was selected.  
 
Data Abstraction 
The data that we abstracted included the first author’s name, year of publication, country of 
origin, cohort design (i.e., prospective or historical cohort), methods for ascertaining diabetes, 
mean follow-up duration, mean or midpoint of participants’ age, proportion of men, baseline 
SUA level, number of participants and events, and adjusted variables. Odds and risk ratios were 
combined as indicators of RR, based on the assumption that the odds ratio is an approximation of 
the risk ratio; this assumption has some limitations, however, especially when the outcome of 
interest is common (5).  
If a study provided several RRs, such as unadjusted and adjusted RRs, the most completely 
adjusted RR was used. Each RR was transformed to its natural logarithm (log RR), and its 
corresponding 95% confidence interval (95% CI) or P value was used to calculate the standard 
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error (SE) for each log RR. Two of our investigators independently reviewed each published 
paper and extracted the relevant information. Any disagreement was resolved by consensus. 
 
Data synthesis 
To quantify the dose-response relationship between the baseline SUA level and risk of T2DM, 
we calculated the RR for each 1 mg/dl increase in SUA in each study. For studies that analyzed 
SUA level not as a continuous but as a categorical variable (i.e., studies where subjects were 
categorized based on SUA level and RRs for the development of T2DM according to SUA level 
were reported), we used the method for trend estimation supported by Berlin et al. and Orsini et 
al. (6, 7). This method is particularly useful when the full data are not available. It enables us to 
correct for covariance between risk estimates from the same study and to estimate the corrected 
linear trend using generalized least squares if data on the adjusted RR and the number of 
participants (or person-time) and cases for each category are provided.  
When the mean SUA level was not reported, the range’s midpoint in each category was used, 
except for the lowest and highest category, for which the mean SUA level was estimated by 
assuming normality of SUA distribution, which is the same method as used in a previously 
published meta-analysis (8). Each log RR was pooled by using a random-effects model (9). The 
overall RR and its 95% CI could be calculated by exponentiation of the pooled log RR. We 
assessed heterogeneity of RRs across studies using both I-squared and Q statistics (10).  
 
Sensitivity analyses 
  The studies included were stratified by key factors related to cohort design (i.e., 
prospective or historical cohort) and other study properties related to study quality and participant 
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characteristics that were identified a priori. Study quality was assessed according to the method 
of ascertainment of diabetes (whether blood measurements, or reports by participants or 
physicians or both), mean follow-up duration (>8 years or ≤8 years) and inclusion of adjustment 
for the following potentially important confounding variables: alcohol intake (Yes or No) and 
metabolic profile (sufficient or insufficient). We regarded the adjustment for metabolic variables 
as sufficient when the risk estimate was adjusted for more than three factors among obesity, 
hypertension (or systolic blood pressure), fasting plasma glucose, HDL-cholesterol and 
triglyceride. We identified country of origin (Asian or Western countries), mean age (>50 years or 
≤50 years), sex (whether men only, women only, or both men and women) and mean SUA level 
(>5.5 mg/dl or ≤5.5 mg/dl) as possible participant characteristics. We calculated the pooled RR 
within the strata of each study characteristic, and meta-regression analyses were conducted to 
assess the effects of these study characteristics on the T2DM risk and incremental increase in 
SUA level.  
The possibility of publication bias was assessed by the Begg’s and the Egger’s tests (11, 12), 
and visual inspection of a funnel plot. We also performed the Duval and Tweedie “trim and fill” 
procedure (13) to further assess the possible effect of publication bias in our meta-analysis. This 
method considers the possibility of hypothetical “missing” studies that might exist, imputes their 
RRs, and recalculates a pooled RR that incorporates the hypothetical missing studies as though 
they actually existed. Data were analyzed by using STATA software version 10 (STATA Corp., 
College Station, TX, USA). P<0.05 was considered as statistically significant except for the test 
of publication bias, in which the level of significance is P<0.10 (14).  
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Results  
Literature Search  
Of 1258 citation retrieved by the search strategy, 1225 citations were excluded after a 
first screening based on titles and abstracts, leaving 33 articles for full-text review. Manual 
searching of the reference lists of these articles identified 8 additional articles. Of the total of 41 
articles for full-text review, 30 articles were excluded for the following reasons: 1) case-control 
studies (6 studies); 2) clinical trials (3 studies); 3) risk estimates of the association of T2DM with 
SUA level were not reported (9 studies); 4) pre-specified outcome did not include T2DM (5 
studies); sufficient data to estimate the RR of T2DM and its corresponding SE per incremental 
increase in UA were not provided (4 studies); 5) data reported were updated by more recent 
studies (3 studies). Eleven studies (15-25) met the inclusion criteria. Three studies investigated 
men and women separately. Finally, 14 cohorts involving a total of 42,834 participants and 3305 
incident cases were included in our analyses.  
   
Study Characteristics  
Characteristics of the eleven included studies are shown in Table 1. Three studies (17, 19, 
23) were prospective cohort and 8 (15, 16, 18, 20-22, 24, 25) were historical cohort. The selected 
studies were published between 1975 and 2009, and the number of subjects per study ranged 
from 250 to 8688. Mean SUA level of subjects ranged from 4.0 to 8.0 mg/dl and mean age 
ranged from 41 to 63 years except for one study (23), in which data on mean age (over 55 years) 
were not available. Four studies (15-17, 19) included men only, and seven (18-21, 23-25) 
included both women and men. Six studies (15, 18, 19, 21, 22, 24) were conducted in Asian 
countries and five (16, 17, 20, 23, 25) in Western countries. Mean follow-up duration ranged 
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from 2.0 to 13.5 years.  
Regarding methods for ascertaining diabetes, four studies (18, 19, 22, 25) used blood 
measurements only, two (17, 20) used reports by participants and/or physicians only, and five (15, 
16, 21, 23, 24) used both. Risk measures were adjusted for alcohol intake in 5 studies (17, 19, 20, 
22, 24), and the adjustment for sufficient metabolic variables was sufficient in 5 studies (18, 
21-24). A few risk estimates were adjusted for smoking status (3 studies) (17, 19, 20), family 
history of diabetes (4 studies) (16, 20, 22, 24) and fasting insulin concentration (3 studies) (18, 21, 
24) . Only two studies (21, 24) considered the effect of serum creatinine, and one study 
considered the effect of diuretic use (25). None of risk measurements was adjusted for other 
drugs that influence SUA level such as alloprinol. 
 
Overall and stratified analyses 
Figure 1 shows a forest plot with RRs and 95% CIs and pooled estimates for the 
reduction in risk of T2DM for each mg/dl increase in SUA. The pooled crude RR (95% CI) was 
1.17 (1.19-1.25). There was evidence of statistical heterogeneity of RRs across studies (Q statistic, 
50.4; I-squared statistic, 74.2%; P<0.001). 
 Table 2 shows findings of the stratified and meta-regression analysis to explore the 
effects of study characteristics. An increased risk of T2DM associated with an incremental 
increase in SUA was consistently found within all strata of each study characteristic (i.e., all 
pooled RRs were greater than 1). There were no significant differences in the pooled risk 
estimates between cohort design (pooled RR [95% CI] of 1.22 [1.10-1.36] for historical cohort 
and 1.10 [1.01-1.20] for prospective cohort, P=0.36). The influence of participant characteristics 
on the study results was not significant. Adjustment for alcohol intake attenuated the association 
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between SUA and T2DM risk (P=0.02), whereas the effect of sufficient adjustment for metabolic 
variables was not significant (P=0.46). 
 
Test of publication bias  
Visual inspection of the funnel plot revealed asymmetry (see online Appendix A). This raises 
the possibility of publication bias, which was statistically supported by the Egger’s test (P=0.06). 
We decided to adjust for this publication bias using the trim and fill method (13). According to 
this method, it was suggested that there were 3 hypothetical negative unpublished cohorts that 
distorted the symmetry of the funnel plot. When these cohorts were incorporated to produce a 
hypothetically symmetrical funnel plot, the association between SUA and T2DM was modestly 
attenuated (RR, 1.10, 95% CI, 1.03-1.20) but remained statistically significant (P=0.009).  
 
 
Conclusions  
Our meta-analysis is the first to summarize the quantitative relationship between SUA levels 
and risk of T2DM, indicating that each 1 mg/dl increase in SUA resulted in a 17% increase in the 
risk of T2DM. Table 3 compares other risk factors of T2DM, established from meta-analysis or 
systematic review (26-29), with SUA. Interestingly, the effect of a 1-mg/dl increment in SUA has 
been found to be comparable to a 1-kg/m2 increment in BMI. 
 
  Pathologically and epidemiologically, it has been indicated that elevated SUA 
concentration is correlated with lifestyle factors (high alcohol intake (30) in particular) and 
various metabolic profiles (especially high values of BMI, blood pressure, FPG and triglycerides, 
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and low HDL cholesterol values (31, 32), which are typically considered to be diagnostic criteria 
for metabolic syndrome (MetS) (33)), leading to a drastic increase in the risk of T2DM (31, 34). 
Therefore, it is possible to establish whether the observed positive association between SUA level 
and risk of T2DM is non-causal. Our sensitivity analysis indicated that a significant association 
was observed if analyses were limited to studies that included adjustment for alcohol intake or 
sufficient metabolic confounders (i.e., more than three metabolic confounders among BMI, 
fasting plasma glucose, hypertension (or systolic blood pressure), HDL cholesterol and 
triglycerides), although the adjustment weakened the association. Therefore, the results of this 
analysis strongly suggest that SUA is an independent predictor of the development of T2DM. 
Therefore, these findings suggest that there are both non-causal and causal associations between 
SUA level and the risk of T2DM.  
The limitations of this meta-analysis must be considered. First, the overall effect estimated 
by the current analysis might be inaccurate due to the statistically significant publication bias. 
According to the results of the compensatory trim and fill method, the overall RR of T2DM for 
each 1 mg/dl SUA increase should be scaled downward by 0.07 to adjust for publication bias. 
However, this method may overestimate the magnitude of any publication bias (35). Moreover, 
this method did not change the statistical significance of the association between SUA level and 
development of T2DM. Therefore, the effect of adjustment for publication bias was probably 
modest. Second, the odds and risk ratios were combined as indicators of RR. The odds ratio 
overestimates the risk ratio, especially when the outcome of interest is common. It is possible that 
this method could distort the overall and stratified analyses within cohort design. The 
overestimation is, however, of little practical importance and can be ignored as long as the pooled 
risk ratio is near to 1 and the total incidence is relatively rare (less than 10%), as they were in our 
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meta-analysis (5). Third, in the sensitivity analysis, the statistical power might be insufficient to 
explain the source of the large study heterogeneity because of the small number of data units 
within strata. For example, there was a substantially larger increase in the risk of elevated SUA 
for development of T2DM observed in Western countries (RR, 1.27) as compared with Asian 
countries (RR, 1.09) and for women (RR, 1.28) as compared with men (RR, 1.09). Although 
these differences were statistically insignificant, we cannot exclude the possibility of the 
influence of race or gender on the association between SUA level and T2DM. This issue might be 
solved by a patient-level meta-analysis, which would be beyond the current meta-analysis. Fourth, 
there were few studies that included a consideration of significant confounders influencing SUA 
level, such as serum creatinine and drugs (e.g., diuretic agents or alloprinol). These confounders 
could contribute to modification of the association between SUA and risk of T2DM. Fifth, we 
thought it was too early to determine whether there is a cut-off level in SUA to increase or reduce 
the risk of development of T2DM because of both the limited number of studies that used SUA 
level as a categorical variable and provided RR data for each category and the variation in 
methods of how SUA levels in each subject were categorized. Therefore, we cannot rule out the 
possibility that SUA level has a threshold effect on the risk of T2DM rather than a dose-response 
effect. 
 
In conclusion, our meta-analysis suggests that SUA level is independently associated with 
the development of T2DM. It is possible that these findings are the first step to utilizing SUA, 
which has been suggested to be a risk factor for T2 DM, in primary care medical practice. Further 
research should attempt to investigate whether SUA would be useful for predicting T2DM with 
respect to the prevention of T2DM; for example, studies should aim to specify the population for 
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which the SUA level is especially important and to determine the SUA threshold for increased 
risk of T2DM.  
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Table 1 Characteristics of studies included in meta-analysis 
First Author Year Cohort  Population Follow- *Diabetes Baseline  Age %Men **No.  No. Cohort 
  designation  up  ascertainment SUA   participants  cases Design 
        (years)   (mg/dl) (years)         
Medalie (15) 1975 IIHDS Israel 5.0  both 4.8  49  100 8688 344 H 
Ohlson (16) 1988 SMB Sweden 13.5  both 5.3  50  100 766 47 H 
Perry (17) 1995 BRHS British 12.8  report 6.0  50  100 7577 194 P 
Chou (18) 1998 KS China 2.0  measure 5.8  50  52  654 39 H 
Taniguchi (19) 2001 OHS Japan 9.5  measure 5.2  41  100 6478 639 P 
Meisinger (20) [men] 2002 MONIKA Germany 7.6  report 5.7  52  100 3052 128 H 
[women]      4.0  51  0 3114 85 H 
Lin (21) [men] 2004 KS China 7.0  both 8.0  49  100 293 27 H 
[women]      7.1  55  0 161 21 H 
Chien (22) 2008 CSCCC China 9.0  measure 5.6  54  43  2690 548 H 
Dehghan (23) 2008 RS Neitherland 10.1  both 5.4  over 55 NA 4536 462 P 
Nan (24) [men] 2008 MNCDS Mauritius 8.2  both 6.6  41  100 1941 337 H 
[women]      5.0  42  0 2318 379 H 
Kraemer(25) 2009 UC USA 13.0  measure 5.7  63 41 566 55 H 
 
Abbreviations: IIHDS, Israel Ischemic Heart Disease Study; SMB, The Study of Men Born in 1913; BRHS, British Regional Heart Study; KS, The Kinmen Study; OHS, The 
Osaka Health Study; MONIKA, MONIKA-Augsberg Cohort Study; JAPF: Japan Arteriosclerosis Prevention Fund; CSCCC, Chin-Shan Community Cardiovascular Center; 
18 
 
RS, The Rotterdam Study; MNCDS, Mauritius Non-Communicable Diseases Surveys; UC; University of California; SUA, serum uric acid; SD, standard deviation; %Men, 
percentage of men; H, historical cohort; P, prospective cohort; NA: not available  
* “measure” means using blood measurements, “report” means using reports by participants or physicians, and “both” means using both blood measurements and reports by 
participants or physicians 
** Number of participants included in the analysis in each study (not necessarily the number of participants at the beginning of each study)
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Table 2.  Stratified and meta-regression analysis to explore the effects of study characteristics 
Study Characteristics No. of *Pooled  P value of 
 cohorts relative risk  
  [95% CI] meta-regression† 
study design    
Historical cohort 10 1.22 [1.10; 1.36] 0.55 
Prospective cohort 4 1.10 [1.01; 1.20]  
    
Indicators of participants characteristics    
Country    
Asia 8 1.09 [1.04; 1.21] 0.10 
Western 6 1.27 [1.12; 1.44]  
Mean age    
≤50 8 1.12 [1.04; 1.19] 0.14 
>50 6 1.26 [1.11; 1.44]  
Sex    
men only 7 1.09 [1.02; 1.16] 0.09 
women only 4 1.28 [1.08; 1.51] 0.31 
both men and women 3 1.40 [0.98; 2.00]  
Mean SUA level    
≤5.5 mg/dl 6 1.18 [1.15; 1.32] 0.98 
>5.5 mg/dl 8 1.16 [1.05; 1.28]  
Indicators of study quality    
Study adjustment for    
alcohol intake    
No 9 1.27 [1.13; 1.43] 0.02 
yes 5 1.07 [1.02; 1.12]  
Metabolic confounders**    
insufficient 8 1.21 [1.09; 1.34] 0.46 
sufficient 6 1.11 [1.02; 1.21]  
Follow-up duration    
≤8 years 6 1.25 [1.03; 1.51] 0.37 
>8 years 8 1.13 [1.05; 1.20]  
Diabetes ascertainment    
blood measurements only 4 1.18 [1.02; 1.37] 0.81 
report only 3 1.24 [0.96; 1.59] 0.64 
both 7 1.14 [1.06; 1.23]  
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* Pooled relative risks of type 2 diabetes for each 1 mg/dl increase in serum uric acid (SUA) within the strata 
of each study characteristics are indicated 
Abbreviation: CI, confidence interval  
** If the relative risks were adjusted for more than 3 confounders (among body mass index, fasting plasma 
glucose, hypertension (or systolic blood pressure), HDL cholesterol and triglycerides), they were regarded as 
“sufficient”; otherwise, they were regarded as “insufficient”. 
† Represents the test for significance of the effect across strata 
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Table 3 Comparison of other risk factors of type 2 diabetes mellitus with incremental 
increase in serum uric acid (SUA) 
Risk factor Relative risk How much of mg/dl in SUA
   is the relative risk 
    comparable to?  
Obesity (26)   
body mass index (per kg/m2) 1.16  1.0  
 waist circumference (per cm) 1.06  0.4  
High alcohol intake (29)   
>3 drinks/day vs. 1 to 3 drinks/day 1.43 2.3  
   
Physical inactivity (27)   
the lowest vs. the highest level **1.20 1.2  
of moderate-intensity physical activity*   
Smoking (28)   
heavy smokers (≥20 cigarettes/day) 1.61 3.1  
vs. non-smokers   
light smokers (<20 cigarettes/day) 1.29 1.7  
vs. non-smokers   
former smoker vs. non-smokers 1.23 1.4  
 
* Typically, no walking vs. ≥2.5 hours/week brisk walking 
** This relative risk is adjusted for body mass index. 
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Figure Legends 
Figure 1. Overall relative risk (RR) (with corresponding 95% confidence intervals (CIs) in 
parentheses) for risk of type 2 diabetes for each mg/dl increase in serum uric acid. The area 
of each square is proportional to study weight. Diamond indicates overall RR; horizontal 
lines indicate 95%CIs.  
 
 
